Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of evobrutinib versus teriflunomide in relapsing multiple sclerosis
MOH_2020-07-07_009123Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evobrutinib in multiple sclerosis (MS) (3 arms), sponsored by Merck KGaA. Primary endpoints: Efficacy and safety of evobrutinib versus teriflunomide and Open-label extension long-term safety and efficacy. Started Jun 2020; status: completed.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2020-07-07_009123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-07-07_009123.